Motexafin lutetium pharmacyclics

IDrugs

Volumn 4, Issue 3, 2001, Pages 351-359

  Yeung, Pollen K F ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 27644557947     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (135)

1. 169854 Corporate Profile. Pharmacydics Inc COMPANY COMMUNICATION 1994
2. 174376 Pharmacydics Gadolite oral MRI imaging agent mid-1995 NDA filing. FDC REPORTS PINK SHEET 1995 57 11 T&G-7 - T&G-8
3. 192710 Pharmacydics files first NDA. SCRIP 1995 2081 15
4. 196902 Pharmacydics' pipeline grows as another product heads to clinic. EMERGING PHARMACEUTICALS1996 5 1 10 -11
5. 203596 Pharmacydics expands photodynamic therapy trial to Stanford. Pharmacydics Inc PRESS RELEASE 1996 March 28
6. 215707 Clinical trial update. BIOWORLD FINANCIAL WATCH 1996 4 31 8
7. 218719 Pharmacydics reports 1996 financial reports. Pharmacydics Inc COMPANY COMMUNICATION 1996 Aug 21
8. 219562 Pharmacydics, Hoechst Celanese forge manufacturing pact for photodynamic therapy and radiation sensitizer products. Pharmacydics Inc PRESS RELEASE 1996 September 12
9. 220610 Clinical trial update March 1996. BIOWORLD FINANCIAL WATCH 19964183-8 Description of phase I data for CVT-124.
10. 220842 Hoechst Celanese's bulk manufacturing for Pharmacydics. SCRIP 1996 2168 10
11. 222622 Manufacturing, marketing and distribution agreements between biotechnology and pharmaceutical companies: July 1996 - September 1996. BIOWORLD FINANCIAL WATCH 1996 4 43 3 - 7
12. 223057 Company results. SCRIP 1996 2174 15
13. 227155 Pharmacyclics Inc - Form 10K, 1996. Pharmacyclics Inc FORM 10K1996 June 30
14. 229288 Pharmacyclics completes phase I Lu-Tex trials in photodynamic cancer treatment Pharmacyclics PRESS RELEASE 1997 January 07
15. 236833 US Clinical trials update. SCRIP 1997 2200 25
16. 237538 Pharmacyclics announces NCI decision network approval to collaborate on two anti-cancer compounds. Pharmacyclics Inc PRESS RELEASE 1997 March 11
17. 239781 DRUG DEV PIPELINE 1997 2 2 1 - 4
18. 246958 Pharmacyclics reports third quarter results. Pharmacyclics Inc PRESS RELEASE 1997 May 01
19. 246982 Pharmacyclics presents results and updates status for photodynamic agent at ASCO meeting. Pharmacyclics Inc PRESS RELEASE 1997 May 20
20. 254354 Annual Report 1996 - Pharmacyclics Inc. Pharmacyclics Inc ANNUAL REPORT 1996 June 30
21. 256165 Localization and efficacy analysis of the photo-therapeutic lutetium texaphyrin (PCI-0123) in the murine EMT6 sarcoma model. Woodbum KW, Fan Q, Miles DR, Kessel D, Luo Y, Young SW PHOTOCHEM PHOTOBIOL 1997 65 3 410 - 415 In vivo study of lutetium texaphyrin for anticancer activity using the murine EMT6 sarcoma model.
22. 256166 Lutetium texaphyrin (PCW123): a near-infrared, water-soluble photosensitizer. Young SW, Woodbum KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC, MHIer RA PHOTOCHEM PHOTOBIOL 1996 63 6 892 - 897 In vivo study of lutetium texaphyrin for anticancer activity using a murine mammary cancer model.
23. 256167 Phototherapy of cancer and atheromatous plaque with texaphyrins. Woodbum KW, Fan Q, Kessel D, Wright M, Mody TD, Hemmi G, Magda D, Sessler JL, Dow WC, Miller RA, Young SW J CLIN LASER MED SURG1996145343-348
24. In vivo study of lutetium texaphyrin for anticancer and anti-atherosclerotic 'activity using the SMT-F murine mammary tumors and a diet-induced rabbit atheromatous plaque model, respectively.
25. 256163 The diagnosis and treatment of atheromatous plaque using texaphyrins. Woodbum KW, Young SW, Qing F, Kesel D, Miller FIA PHOTOCHEM PHOTOBIOL 1996 63 Spec Iss 103S
26. 256169 Biological analysis of lutetium texaphyrin (PCI-0123). Woodbum KW, O:ng F, Miles DR, Kessel D, Young SW PHOTOCHEM PHOTOBIOL 1996 63 Spec Iss 80S
27. 256171 In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. Ehrenberg B, Kostenich G, Orenstein A, Roitman L, Malik 7. PHOTOCHEM PHOTOBIOL 1996 63 Spec Iss 23S
28. 256173 Evaluation of lutetium texaphyrin in thé photodynamic therapy of malignant neoplasms. Young SW, Wright M, Mody T, Sessler J, Woodbum K, Dow W, Miller RA PHOTOCHEM PHOTOBIOL 1995 61 5 Suppl 81S
29. 256174 Lutetium(lll) texaphyrin: A novel photodynamic therapy agent. Mody TD, Wright M, Linquist V, Young SW, Sessler JL, Harriman A, Berns M, Miller RA PHOTOCHEM PHOTOBIOL 1994 59 Spec Iss 37S
30. 260778 Pharmacyclics Reports 1997 Financial Results. Pharmacyclics Inc PRESS RELEASE 1997 August 28
31. 266502 Pharmacyclics announces licensing agreement with Nycomed for cancer photosensitizer. Pharmacyclics Inc PRESS RELEASE 1997 October 20
32. 267752 Nycomed licenses Pharmacyclics' photosensitizer. SCRIP 1997 227913
33. 270142 Synthesis and structural characterization of Lanthanide(lll) Texaphyrins. Sessler JL, Mody TD, Hemmi GW, Lynch V INORGANIC CHEM1993 32 3175 - 3187 Chemical synthesis of lutetium texaphyrins.
34. 270143 An "Expanded Porphyrin": The synthesis and structure of a new aromatic pentadentate ligand. Sessler JL, Murai T, Lynch V, Cyr M J AM CHEM SOC1988 110 5586 - 5588 Chemical synthesis of lutetium texaphyrins.
35. 270144 Texaphyrins: Synthesis and applications. Sessler JL, Hemmi G, Mody TD, Murai T, Burrell A, Young SW ACC CHEM RESEARCH 1994 27 43 - 50 Chemical synthesis of lutetium texaphyrins
36. 270145 Phase I trial of photodynamic therapy with lutetium-texaphyrin (LU-TEX). Yuen AR, Panella TJ, Wieman TJ, Julius C, Panjehpour M, Taber S, Rngar V, Homing SJ, Miller RA, Young SW, Renischier MF PROC AM SOC CLIN ONCOL 1997 16 Abs 768.5 Phase I clinical trial of lutetium texaphyrins.
37. 270261 Annual Report 1997 - Pharmacyclics. Pharmacyclics Inc ANNUAL REPORT1997 June 30
38. 272221 Pharmacyclics Inc COMPANY WORLD WIDE WEB SITE 1997 December 15
39. 272807 Pharmacyclics signs ophthalmology deal with Alcon for photosensitizer. Pharmacyclics Inc PRESS RELEASE 1997 December 17
40. 274932 Pharmacyclics/Alcon deal on Lu-Tex. SCRIP 1998 2299 9
41. 275096 Immunomodulatory aspects of photodynamic therapy. Hunt D, Levy J EXP OPIN INVEST DRUGS 1998 7 57 - 64
42. 275428 BancAmerica Robertson Stephens: Health Care Research: Miravant Medical Technology. BancAmerica Robertson Stephens ANALYST REPORT 1997 November 03
43. 275S49 Texaphyrin-based chemosensitising agents. EXP OPIN THER P.47199881 91 -93
44. 277607 Pharmacyclics reports second quarter results. Pharmacyclics Inc PRESS RELEASE 1998 February 13
45. 281210 Pharmacycücs Ine - Form 10K, 1997. Pharmacyclics Ine FORM 10K1997 June 30
46. 283196 BancAmerica Robertson Stephens: Biotechnology Industry Product Compendium. BancAmerica Robertson Stephens ANALYST REPORT 1998 March 6
47. 287674 Laserscope's POT laser systems to be Included In phase I clinical trial for treatment of atherosclerosis. Pharmacyclics Inc PRESS RELEASE 1998 May 19
48. 291175 Lutetium texaphyrin (Lu-Tex) photodynamic therapy of patients with refractory locally recurrent breast cancer. Panella TJ, Wieman TJ, Dougherty S, Yuen A, Cartson R, Esserman L, Woodbum K, Engel J, Miller RA, Renschler MF PROC AM SOC CLIN ONCOL 1998 17 Abs 632
49. 291754 Pharmacyclics' Antrin photoangioplasty data presented at American Society For Photobiology meeting; preliminary phase I data demonstrate activity in atherosclerosis. Pharmacyclics Inc PRESS RELEASE 1998 July 15
50. 296440 Pharmacyclics reports 1998 financial results. Pharmacyclics Inc PRESS RELEASE 1998 August 27
51. 297016 FDA advisory committee recommends approval of photodynamic therapy for advanced lung cancer using Laserscope's POT systems company now participating In seven PDT programs. QLT Photo-Therapeutics Inc PRESS RELEASE 1998 September 3
52. 304358 Pharmacyclics' Antrin demonstrates activity in photoangioplasty treatment of atherosclerosis - interim phase I data presented at American Heart Association Meeting. Pharmacyclics Inc PRESS RELEASE 1998 November 9
53. 305950 Drug development pipeline. DRUG DEV PIPELINE 1998 3 7 1
54. 307498 Pharmacyclics' Antrin photoangioplasty presented as a 'hot topic' paper at RSNA updated interim phase I results presented. Pharmacyclics Inc PRESS RELEASE 1998 November 30
55. 319141 Pharmacyclics' ANTRIN photoangioplasty trial demonstrates activity in atherosclerosis. Pharmacyclics Inc PRESS RELEASE 1999 March 22
56. 319278 Light-activated drug shrinks plaque buildup in arteries. Stanford University PRESS RELEASE 1999 March 23
57. 322502 Pharmacyclics receives payment from Alcon to continue development of lutetium texaphyrin for ophthalmology. Pharmacyclics Inc PRESS RELEASE 1999 April 23
58. 322840 Pharmacyclics completes enrollment In phase I Antrin trial for atherosclerosis. Pharmacyclics Ino PRESS RELEASE 1999 April 27
59. 323929 Pharmacyclics reports third quarter results. Pharmacyclics Inc PRESS RELEASE 1999 May 6
60. 323952 Pharmacyclics Inc COMPANY WORLD WIDE WEB SITE 1999 May 07 Information on Pharmacyclics projects
61. 325083 Pharmacyclics presents results of phase II Lutrin trial for photodynamic therapy of breast cancer data reported at ASCO demonstrates activity In patients with advanced refractory chest wall disease. Pharmacyclics Inc PRESS RELEASE 1999 May 17
62. 325878 A preclinical trial of interstitial PDT in the canine prostate. Hsi RA, Glastein E PROCAMASSOC CANCER RES 1999 40 Abs 3463
63. 325967 Photodynamic therapy (PDT) of locally recurrent breast cancer (LRBC) with lutetium texaphyrin (Lutrin): a Phase IB/HA trial. Wieman TJ, Panella T, Lustig R, Liebmann J, Cartson R, Esserman L, Dougherty S, Fingar V, Hoth D, Renschler M, Adelman D PROC AM SOC CLIN ONCOL 1999 18 May 15-18418
64. 329593 Pharmacyclics announces clinical results with lutetium texaphyrin for treatment of age-related macular degeneration. Pharmacyclics Inc PRESS RELEASE 1999 June 28
65. 330750 Photodynamic therapy in historical perspective. Bonnen R REV CONTEMPPHARMACOTHERt399 10 1 1 -17 A review of the history of photodynamic therapy.
66. 334979 Summary of the American Society of Clinical Oncology 35th Annual Meeting, Atlanta, GA, USA. McKinnon C IDDB MEETING REPORT 1999 May 15-18
67. 336332 Pharmacyclics reports 1999 financial results. Pharmacyclics Inc PRESS RELEASE 1999 August 12
68. 338308 Pharmacyclics reports phase I data indicating safety and clinical activity of Antrin Photoangloplasty. Pharmacyclics Inc PRESS RELEASE 1999 August 30
69. 341341 Pharmacyclics announces Antrin photoangioplasty phase II clinical trial patient treated during live case demonstration at TCT clinical data also presented at annual meeting of interventional cardiologists. Pharmacyclics Inc PRESS RELEASE 1999 September 27
70. 347151 Pharmacyclics announces final phase I study results of arrtrin photoangioplasty at AHA meeting - new preclinical studies also demonstrate treatment reduces atherosclerosis by eliminating inflammatory cells. Pharmacyclics Inc PRESS RELEASE 1999 November 10
71. 348919 Annual Report 1999 - Pharmacyclics Inc. Pharmacyclics Inc ANNUAL REPORT 1999 June 30
72. 352044 Pharmacyclics receives milestone payment from Alcon to continue development of optrin for ophthalmology. Pharmacyclics Inc PRESS RELEASE2000 January 10
73. 353196 Photodynamic therapy of B16F10 murine melanoma with lutetium texaphyrin. Woodbum KW, Fan Q, Kessel D, Luo Y, Young SW J INVESTDERMATOL 1998 110 5 746 - 751 Anticancer effect of photo-dynamic therapy using lutetium texaphyrin in the B16F10 murine melanoma model.
74. 353198 Photoangioplasty with ANTRIN: A photosensitizer that selectively accumulates in atheromatous plaque and is detectable by fluorescence imaging. Woodburn KW, Fan Q, Thiemann P, Kessel D CIRCULATION 1998 98 17 I66
75. 353200 Evaluation of texaphyrins as tumor selective radiation sensitizers. Fan Q, Woodbum KW, Young SW INT J RADIAT ONCOL BIOL PHVS1997392256
76. 353201 Photoangioplasty following intravenous lutetium texaphyrin: A far red, light activated photodynamic therapy agent that selectively accumulates in atheroma. Woodbum KW, Fan Q, Young SW CIRCULATION 1997 96 8 1135
77. 353202 Photoeradication of atheromatous plaque with lutetium texaphyrin. Young SW, Fan Q, Thiemann P, Kessel D, Woodbum KW PHOTOCHEM PHOTOBIOL 1997 65 60s
78. 353204 Photodynamic therapy of pigmented melanoma with lutetium texaphyrin. Woodbum W, Fan Q, Kessel D, Luo Y, Young SW PHOTOCHEM PHOTOBIOL 1997 6 59s
79. 353207 Repeated treatment of RIF-1 tumors with photodynamic therapy (PDT) using lutetium texaphyrin (PCI-0123). Miles DR, Young SW PHOTOCHEM PHOTOBIOL 1997 65 47s
80. 353209 Biological analysis of lutetium texaphyrin (PCI-0123). Woodbum KW, Qing F, Miles DR, Kessel D, Young SW PHOTOCHEM PHOTOBIOL 19966380s
81. 353211 Lutetium texaphyrin (PCI-0213): A near-infrared, water-soluble photosensitizer. Young SW, Woodbum KW, Wright M, Mody TD, Fan Q, Sessler JL, Dow WC, Miller RA PHOTOCHEM PHOTOBIOL 1996 63 70s
82. 354455 Pharmacyclics reports second quarter results. Pharmacyclics Inc PRESS RELEASE 2000 February 03
83. 357602 Pharmacyclics announces start of phase I clinical trial of Antrin photoangioplasty for coronary artery disease. Pharmacyclics Inc PRESS RELEASE2000 February 29
84. 362693 Intraperitoneal photodynamic therapy with motexafin lutetium In a canine model. Hahn S M, Griffen G M, Kachur A, Vulcan T, Solonenko M, Busch T M, Kapatkin A, Yodh A, Glatstein E, Zhu T PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 3904
85. 362897 Evaluation of the plasma pharmacokinetics (PK) of motexafin lutetium (lutetium texaphyrin) in multiple species. Miles D, Shemirani A, Upadhyay S, Lacy S PROC AM ASSOC CANCER RES 2000 41 April 1-5 Abs 4482
86. 364437 Summary of the American Association for Cancer Research 91st Annual Meeting, San Francisco, CA, USA. Worker C, Brown H IDDS MEETING REPORT2000 April 1-5
87. 365074 Pharmacyclics announces preliminary results from ongoing phase II dose-ranging study with Optrin for the treatment of age-related macular degeneration; clinical results presented at ARVO annual meeting. Pharmacyclics Inc PRESS RELEASE 2000 May 03
88. 365219 Pharmacyclics reports third quarter results. Pharmacyclics Inc PRESS RELEASE2000 May 04
89. 375266 Gruntal & Co - AVAX Technologies Inc. Gruntal & Co ANALYST REPORT2QOO June 08 1 - 28
90. 380234 Pharmacyclics reports fourth quarter and fiscal 2000 financial results. Pharmacyclics Inc PRESS RELEASE 20QQ August 24
91. 380647 Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Sessler JL, Miller RA BIOCHEM PHARMACOL 2000 59 7 733 - 739
92. 380658 Clinical trials referral resource. Clinical trials with gadoliniumtexaphyrin and lutetium-texaphyrin. Ivy SP, Blatner G, Cheson BD ONCOL USA1999135671 -676
93. 380746 Cancer gets the red light: Pharmacyclics, Inc. Wells WA CHEM BIOL 1997 4 10 775 -776
94. 381223 One-electron reduction and oxidation studies of the radiation sensitizer gadolinium(lll) texaphyrin (PCI-0120) and other water soluble metallotexaphyrins. Sessler JL, Tvermoes NA, Guldi DM, Mody TD, Alien VIEJPHYS CHEM A1999 103 787 - 794
95. 381224 Models of cytotoxicity associated with photodynamic therapy. Kessel D, Luo Y, Chang CK, Henderson BW, Woodbum KW PROC SPIE-INT SOC OPT ENG 1997 2972 103-109
96. 382470 Texaphyrins: An overview. Pharmacyclics Inc COMPANY WORLD WIDE WEB SITE2000 September 16
97. 382636 Lutetium texaphyrin (Lu-Tex): a potential new agent for ocular fundus angiography and photodynamic therapy. Blumenkranz MS, Woodbum KW, Qing F, Verdooner S, Kessel D, Miller R AM J OPHTHALMOL 20001293353-362
98. An in vivo evaluation of lutetium texaphyrin as an image agent for retinal vascular and choroidal vascular diseases.
99. 382638 Update on photodynamic therapy. Regillo CO CURB OPIN OPHTHALMOL 200011 3 166 -170 A review and update on photodynamic therapy.
100. 382639 Subcellular phototoxicity of Photofrin-ll and lutetium texaphyrin in cells in vitro. Liang H, Shin DS, Lee YE, Nguyen DC, Kasravi S, Do T, Aurasteh P, Berns MW LASERS MED SCI 200015 2 109 -122 An in vitro study of subcellular localization and phototoxicity of photofrin-ll and lutetium texaphyrin.
101. 382641 Fluorescence pharmacokinetics of Lutetium Texaphyrin (PCI0123, Lu-Tex) in the skin and in healthy and tumoral hamster cheekpouch mucosa. Zellweger M, Radu A, Monnier P, Van Den Bergh H, Wagnieres G J PHOTOCHEM PHOTOBIOL B BIOL 2000 55 1 56 - 62
102. 382643 Photodynamic therapeutics: Basic principles and clinical applications. Sharman WM, Allen CM, Van Lier JE DRUG DISC TODAY 1999411 507-517 A review of photodynamic therapy for cancer.
103. 382645 Photodynamic activity of lutetium-texaphyrin in a mouse tumor system. Hammer-Wilson MJ, Ghahramanlou M, Berns MW LASERS SURG MED 1999 24 4 276 -284 An in vivo study of the photodynamic activity of lutetium texaphyrin in a mouse tumor model.
104. 382646 Photodynamic parameters in the chick chorioallantoic membrane (CAM) bioassay for topically applied photosensitizers.
105. Hammer-Wilson MJ, Akian L, Espinoza J, Kimel S, Berns MW J PHOTOCHEM PHOTOBIOL B BIOL 1999 53 1 -3 44 - 52 A comparsion of photodynamic parameters between different photosensitizers.
106. 382648 Systemic application of photosensitizers in the chick chorioallantoic membrane (CAM) model: photodynamic response of CAM vessels and 5-aminolevulinic acid uptake kinetics by transplantable tumors. Homung R, Hammer-Wilson MJ, Kimel S, Liaw LH, TadirY, Berns MW J PHOTOCHEM PHOTOBIOL B BIOL 199949 1 41 -49
107. 382650 In vitro and in vivo comparison of argon-pumped and diode lasers for photodynamic therapy using second-generation photosensitizers. Hammer-Wilson MJ, Sun CH, Ghahramanlou M, Berns MW LASERS SURG MED 1998 23 5 274 - 280
108. 382651 What does photodynamic therapy have to offer radiation oncologists (or their cancer patients)? Stewart F, Baas P, Star W RADIOTHER ONCOL 1993 48 3 233 - 248 A review of photodynamic therapy in radiation oncology.
109. 382653 In vivo photodynamic therapy with the new near-IR absorbing water soluble photosensitizer lutetium texaphyrin and a high intensity pulsed light delivery system. Kostenich G, Orenstein A, Roitman L, Malik Z, Ehrsnberg B J PHOTOCHEM PHOTOBIOL B BIOL 1997 39 1 36 - 42 An in vivo study of the photodynamic effect of lutetium texaphyrin in a mouse tumor model.
110. 382659 Evaluation of the plasma pharmacokinetics (PK) of motexafin lutetium (lutetium texaphyrin) in multiple species. Miles 6, Shemirani A, Upaahyay S, Lacy S PROCAM ASSOC CANCER RES 2000 41 705
111. 382661 Photodynamic therapy using Lu-Tex induces apoptosis in vitro and its effect is potentiated by angiostatin in retinal capillary endothelial cells. Renno RZ, Delori FC, Holzer RA, Gragoudas ES, Miller JW ANN MEET ASSOC RES VISION OPTHTALMOL 2000 41 4 S531
112. 382664 Preliminary results from a Phase II Dose-Response study of photodynamic therapy with motexafin lutetium (Lu-Tex™) to treat subfoveal CNV. Blumenkranz MS, Miller JW, Guyer DR, Slakter JS, Sickenberg M, Zilliox P, Jerdan J ANN MEET ASSOC RES VISION OPTHTALMOL 2000 41 4 S531
113. 382678 Determinants of the apoptotic response to lysosomal photodamage. Kessel D, Luo Y, Mathieu P, Reiners JJ PHOTOCHEM PHOTOBIOL 2000 71 2 196 - 200
114. 382680 Photodynamic therapy in the treatment of cancer: Current state of the art Hsi RA, Rosenthal DI, Glatstein E DRUGS 1999 57 5 725 - 734
115. 382681 Digital angiography using lutetium texaphyrin in a monkey model of choroidal neovascularization. Graham KB, Arbour JD, Connolly EJ, Delori F, Carson D, Gragoudas ES, Miller JW ANN MEET ASSOC RES VISION OPTHTALMOL 1999 40 4 S402
116. 382683 Photodynamic therapy of experimental choroidal neovascularization in a monkey model using intravenous infusion of lutetium texaphyrin. Arbour JD, Connolly EJ, Graham K, Carson D, Michaud N, Rotte T, Gragoudas ES, Miller JW ANN MEET ASSOC RES VISION OPTHTALMOL 1999 40 4 S401
117. 382685 Antrin photoangioplasty: Results of a phase I trial of a novel therapeutic modality in patients with lower extremity arterial atherosclerosis. Krämer P, Rockson S, Razavi M, Adelman D EUR HEART J . 199920155
118. 382692 - Photoangioplasty of human atherosclerosis with lutetium texaphyrin. Rockson SG, Kramer P, Razavi M, Szuba A, Rlardo S, Cooke JP, Adelman D PHOTOCHEM PHOTOBIOL 1999 69 49s
119. 382694 Reduction of atheromatous plaque with ANTRIN™ photoangioplasty. Woodbum KW, Fan Q, Miller R PHOTOCHEM PHOTOBIOL 1999 69 19S - 20S
120. 382696 Photoangioplasty with lutetium texaphyrin reduces atheroma and eliminates macrophages in a rabbit balloon injury model. Hayase M, Woodbum KW, Perloth J, Miller R, Baumbardner W, Yock PG, Yeung AC CIRCULATION 1999 11018 Suppl I306
121. 382697 Photodynamic therapy with lutetium texaphyrin induces apoptosis of vascular cells. Simon DI, Woodbum KW, Xu H, Cheong W F, Raman V, Adelman D, Miller RA, Rogers C CIRCULATION 1999 110 18 Suppl I700
122. 382699 Photoangioplasty of atherosclerosis with lutetium texaphyrin (Lu-Tex): Results of a phase I study in peripheral arterial disease.
123. Rockson SG, Kramer P, Razavi MK, Szuba A, Steven D, Adelman D CIRCULATION 1999 11018 Suppl 1672
124. 382700 Reduction of vein graft disease using photodynamic therapy with lutetium texaphyrin in a rodent isograft model. Yamaguchi A, Woodbum KW, Hayase M, Hoyt G, Robbins RC CIRCULATION 1999 11018 Suppl I665
125. 382702 Lutetium texaphyrin angiography: A new method for the evaluation and treatment of retinal and choroidal vascular disorders. Blumenkranz MS, Woodbum K, Verdooner S ANN MEET ASSOC RES VISION OPTHTALMOL 1998 39 4 S468
126. 382704 Photophysics, photobiology and in vivo pharmacokinetics of the near-IR absorbing water soluble sensitizer lutetium texaphyrin. Ehrenberg B, Lavi A, Kostenich G, Babushkin T, Malik 7. PHOTOCHEM PHOTOBIOL 1997 65 68S
127. 382707 Photodynamic therapy trials with lutetium texaphyrin PC 1-0123 (Lu-Tex). Renschler MF, Yuen A, Panella TJ, Wieman TJ, Julius C PHOTOCHEM PHOTOBIOL 1997 65 47S - 48S
128. 388334 Pharmacyclics reports first quarter results. Pnarmacyclics Inc PRESS RELEASE2000 November 02
129. 389698 Pharmacyclics announces preliminary phase I study results of Antrin photoangioplasty for coronary artery disease. Pharmacyclics Inc PRESS RELEASE2000 November 14
130. 390004 American Heart Association 73rd Scientific Sessions - Overnight Report (Part III) New Orleans, LA, USA Ahmed T IDDB MEETING REPORT 2000 November 12-15
131. 390775 Coronary photoangioplasty using motexafin lutetium (Antrin): Early finding of a phase I trial In patients undergoing stent implantation. Kereiakes DJ, Synisszewski AM, Simon Dl, rogers C, Wahr DW, Adelman DC, Chou TM CIRCULATION 2000 102 18 2739
132. 391738 Summary of the American Heart Association, 73rd Scientific Sessions, New Orleans, LA, USA. Croasdell G IDDB MEETING REPORT 2000 November 12-15
133. 392354 Photodynamic therapy with verteporfin (Visudyne) for macular degeneration. MED LETTER 2000 42 1086 81 - 82
134. 396760 Pharmacyclics Inc. HAMBRECHT& QUIST 2001 January 8-11 284 Conference Book for the 19th Annual JP Morgan H&Q Healthcare Conference.
135. 397085 Summary of the JP Morgan Hambrecht & Quist 19th Annual Healthcare Conference, San Francisco, CA, USA. Croasdell G IDDB MEETING REPORT2001 January 8-11